FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

STAHL NEIL
2. Issuer Name and Ticker or Trading Symbol

REGENERON PHARMACEUTICALS, INC. [ REGN ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
EVP Research and Development
(Last)          (First)          (Middle)

777 OLD SAW MILL RIVER ROAD
3. Date of Earliest Transaction (MM/DD/YYYY)

2/12/2020
(Street)

TARRYTOWN, NY 10591
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 2/12/2020  M(1)  25000 A$52.03 36380 D  
Common Stock 2/12/2020  F(1)  14722 D$402.34 21658 D  
Common Stock 2/13/2020  S(1)  4302 D$399.8 (2)17356 D  
Common Stock 2/13/2020  S(1)  2608 D$400.54 (3)14748 D  
Common Stock 2/13/2020  S(1)  2058 D$401.46 (4)12690 D  
Common Stock 2/13/2020  S(1)  1279 D$402.35 (5)11411 D  
Common Stock 2/13/2020  S(1)  31 D$406.44 11380 D  
Common Stock         5736 I By 401(k) Plan 
Common Stock         7831 I by 2018 GRAT 
Common Stock         13700 I by 2019 GRAT 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-Qualified Stock Option (right to buy) $52.03 2/12/2020  M (1)    25000   (6)12/16/2021 Common Stock 25000 $0.0 63079 D  

Explanation of Responses:
(1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
(2) Represents volume-weighted average price of sales of 4,302 shares of Company stock on February 13, 2020 at prices ranging from $399.04 to $399.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price.
(3) Represents volume-weighted average price of sales of 2,608 shares of Company stock on February 13, 2020 at prices ranging from $400.01 to $400.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price.
(4) Represents volume-weighted average price of sales of 2,058 shares of Company stock on February 13, 2020 at prices ranging from $401.11 to $401.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price.
(5) Represents volume-weighted average price of sales of 1,279 shares of Company stock on February 13, 2020 at prices ranging from $402.04 to $402.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price.
(6) With respect to 75,000 underlying shares (of which 50,000 remain outstanding), the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. With respect to 48,079 underlying shares (of which 13,079 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
STAHL NEIL
777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591


EVP Research and Development

Signatures
/s/**Neil Stahl2/14/2020
**Signature of Reporting PersonDate

Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Apr 2020 to May 2020 Click Here for more Regeneron Pharmaceuticals Charts.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From May 2019 to May 2020 Click Here for more Regeneron Pharmaceuticals Charts.